ClinicalTrials.gg
CompletedNCT05628103Updated Dec 11, 2025Results posted

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

A Phase 3 interventional study of SEP-363856 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
10th of 23
101 · median 83
Started
2022
with 4 others
Phase 3
9 of 23
1 open now
Registered
19th of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 10th largest by enrollment, is one of 5 that started in 2022, is one of 9 in phase 3, and was the 19th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.

Read the detailed description

This was an 8-week, outpatient, multicenter, open-label, single-group, flexible-dose study.

Following a screening period of up to 21 days, eligible participants took part in the study. In the 8-week treatment period, participants were treated with SEP-363856 while continuing to take the full dose of their pre-switch antipsychotic. After the end of the treatment period, participants were required to complete the follow-up visit, 7 days after the last dose of SEP-363856.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: This list is not all inclusive

  • Participants meets , Fifth Edition (DSM-5) criteria for a diagnosis of schizophrenia.
  • Participants are judged to be clinically stable (ie, no evidence of an acute exacerbation of schizophrenia) by the Investigator for at least 8 weeks prior to Baseline.
  • Participants must be judged by the Investigator to be an appropriate candidate for switching current antipsychotic medication due to safety or tolerability concerns and/or insufficient efficacy.
  • Participants are taking an oral antipsychotic and the antipsychotic regimen has been stable for at least 6 weeks prior to Screening.

Exclusion Criteria:This list is not all inclusive

  • Participant has a current DSM-5 diagnosis or presence of symptoms consistent with a major psychiatric disorder, other than schizophrenia, that is the primary focus of treatment.
  • Participants are at significant risk of harming self or others based on investigator's judgment.
  • Participant has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in the study.
  • Female participant who is pregnant or lactating.
  • Participant tests positive for drugs of abuse at Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    SEP-363856

    Participants received flexible doses of SEP-363856 50 to 100 milligrams per day (mg/day), orally, once daily (QD) up to Week 8. The dose was titrated up from 50 mg/day on Days 1 to 3, to 75 mg/day on Days 4 to 7. Beginning Day 8, the dose was adjusted within the range of 50 mg/day to 100 mg/day in 25 mg increments (i.e. 50, 75, or 100 mg/day) up to Week 8.

    Drug: SEP-363856

Interventions

  • SEP-363856 flexibly dosed for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Discontinued From the Study Due to Clinical Reasons

    Discontinuation for clinical reasons was defined as reasons due to adverse event (AE) or lack of efficacy. AEs are defined as untoward medical occurrences that started at the same time of or after the first dose of study drug. The percentage of participants who discontinued for clinical reasons was calculated by a proportion consisting of the number of participants who experience a discontinuation event due to clinical reasons as the numerator divided by the number of participants in the safety population as the denominator multiplied by 100 along with a corresponding 95% confidence interval (CI). 95% CI was calculated using the normal approximation method.

    Time frame: From the first dose of the study drug up to end of follow up (up to Week 9)

Secondary outcomes

  1. Percentage of Participants Who Discontinued From the Study Due to Any Reason

    The percentage of participants who discontinued from the study due to any reason was calculated by a proportion consisting of the number of participants who experience a discontinuation event due to any reason as the numerator divided by the number of participants in the safety population as the denominator multiplied by 100 along with a corresponding 95% CI. 95% CI was calculated using the normal approximation method.

    Time frame: From first dose of the study drug up to end of follow-up period (up to Week 9)

07

Results

Posted Nov 12, 2025

Participant flow

Participants took part in the study at 26 clinical sites in the United States (US) from 19 December 2022 to 01 April 2024.

Participant flow — Overall Study
MilestoneSEP-363856
Started101
Safety population101
Completed83
Not completed18
Withdrew: Adverse event7
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up3
Withdrew: Lack of efficacy1
Withdrew: Non-compliance with study drug4

Outcome measures

PrimaryPercentage of Participants Who Discontinued From the Study Due to Clinical Reasons

Discontinuation for clinical reasons was defined as reasons due to adverse event (AE) or lack of efficacy. AEs are defined as untoward medical occurrences that started at the same time of or after the first dose of study drug. The percentage of participants who discontinued for clinical reasons was calculated by a proportion consisting of the number of participants who experience a discontinuation event due to clinical reasons as the numerator divided by the number of participants in the safety population as the denominator multiplied by 100 along with a corresponding 95% confidence interval (CI). 95% CI was calculated using the normal approximation method.

Time frame:
From the first dose of the study drug up to end of follow up (up to Week 9)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued From the Study Due to Clinical Reasons
percentage of participantsSEP-363856
Percentage of Participants Who Discontinued From the Study Due to Clinical Reasons7.9 (2.7 to 13.2)
SecondaryPercentage of Participants Who Discontinued From the Study Due to Any Reason

The percentage of participants who discontinued from the study due to any reason was calculated by a proportion consisting of the number of participants who experience a discontinuation event due to any reason as the numerator divided by the number of participants in the safety population as the denominator multiplied by 100 along with a corresponding 95% CI. 95% CI was calculated using the normal approximation method.

Time frame:
From first dose of the study drug up to end of follow-up period (up to Week 9)
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued From the Study Due to Any Reason
percentage of participantsSEP-363856
Percentage of Participants Who Discontinued From the Study Due to Any Reason17.8 (10.4 to 25.3)

Adverse events

Collected over From first dose of study drug up to end of follow up period (up to Week 9). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SEP-3638560/101 (0%)4/101 (4%)13/101 (12.9%)
Most frequent serious events
Most frequent serious events
EventSEP-363856
SchizophreniaPsychiatric disorders4/101
Most frequent other events
Most frequent other events
EventSEP-363856
DizzinessNervous system disorders5/101
InsomniaPsychiatric disorders4/101
Dry mouthGastrointestinal disorders3/101
NauseaGastrointestinal disorders3/101

Baseline characteristics

Safety population included all participants that were enrolled and received the study drug.

Age, Continuous
Age, Continuous(years)SEP-363856
Mean48.1 ± 12.02
Sex: Female, Male
Sex: Female, Male(Participants)SEP-363856
Female29
Male72
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SEP-363856
Hispanic or Latino18
Not Hispanic or Latino83
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SEP-363856
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American64
White32
More than one race1
Unknown or Not Reported1
08

Study locations

25 sites
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Clinical Innovations Inc.
    Bellflower, California 90706, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Collaborative Neuroscience Research, LLC
    Garden Grove, California 92845, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Clinical Innovations, Inc
    Riverside, California 92506, United States
  • California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)
    San Diego, California 92102, United States
  • CMB Clinical Trials
    Santee, California 92071, United States
  • Cenexel CNS Research
    Torrance, California 90502, United States
  • Larkin Behavioral Health Services
    Hollywood, Florida 33021, United States
  • Premier Clinical Research Institute, Inc.
    Miami, Florida 33122, United States
  • Wellness Research Center
    Miami, Florida 33135, United States
  • Nova Psychiatry, Inc.
    Orlando, Florida 32803, United States
  • Advanced Discovery Research LLC
    Atlanta, Georgia 30318, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Atlanta Behavioral Research
    Atlanta, Georgia 30358, United States
  • Uptown Research
    Chicago, Illinois 60640, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • PsychCare Consultants Research
    St Louis, Missouri 63128, United States
  • IMA Clinical Research
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • New Hope Clinical Research
    Charlotte, North Carolina 28211, United States
  • Clinical Trials of America, LLC
    Hickory, North Carolina 28601, United States
  • Charak Clinical Research Center
    Garfield Heights, Ohio 44125, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Apr 2024, 15 months.

Results were first posted in Nov 2025, 1 year 7 months after primary completion. A results delay was requested in Mar 2025.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 15 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Nov 28, 2022
StartActual
Dec 19, 2022
Primary completionActual
Apr 1, 2024
CompletionActual
Apr 1, 2024
Results delay requested
Mar 28, 2025
Results first posted
Nov 12, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05628103
Responsible party
Sponsor
First posted
Nov 28, 2022
Start date
Dec 19, 2022
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024
Results posted
Nov 12, 2025
Last update
Dec 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion